Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
HAE > SEC Filings for HAE > Form 8-K on 25-Jul-2014All Recent SEC Filings

Show all filings for HAEMONETICS CORP

Form 8-K for HAEMONETICS CORP


25-Jul-2014

Entry into a Material Definitive Agreement, Change in Directors or Principal Off


ITEM 1.01 Entry into a Material Definitive Agreement.

On July 23, 2014, the Haemonetics Corporation stockholders and Board of Directors approved an amendment to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan to (i) increase the number of shares issuable under the Plan by 4,800,000 shares, (ii) extend the term of the Plan, and (iii) alter the rate at which certain awards are counted toward Plan limits. A restated copy of the Plan is filed herewith as Exhibit 10.1.



ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On July 23, 2014, Paul Black notified Haemonetics Corporation (the "Company") that after serving on the board since 2011, he will resign his position effective July 31, 2014. Mr. Black's decision was based on his desire to focus more of his time in his role as Chief Executive Officer and President of Allscripts Healthcare Solutions, Inc., a public healthcare solutions company, and does not reflect any disagreement with the Company on any matter relating to the Company's operations, policies or practices. .



ITEM 5.07 Submission of Matters to a Vote of Security Holders.

Haemonetics Corporation's Annual Meeting of Stockholders was held on July 23, 2014. At the Meeting:

1. Brian P. Concannon, Ronald L. Merriman and Charles J. Dockendorff were elected to serve as directors of Haemonetics Corporation;

2. Amendments to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan which (i) increase the total number of shares available for grant, (ii) extend the term of the Plan, and (iii) alter the rate at which certain awards are counted toward Plan limits were approved;

3. Advisory vote regarding the compensation of our named executive officers was approved; and

4. The selection of Ernst & Young LLP to serve as the independent registered public accounting firm of Haemonetics Corporation for fiscal year 2015 was ratified.

Below are the number of votes cast for or against, the number of abstentions, the number of votes withheld and the number of broker non-votes:

Election of Directors:
       Director        Votes For  Withheld  Non-Vote
  Brian P. Concannon   45,232,892  796,976  1,750,862
  Ronald L Merriman    43,917,863 2,112,005 1,750,862

Charles J. Dockendorff 45,244,673 785,195 1,750,862

Amendments to Long-Term Incentive Compensation Plan:
Votes For Votes Against Abstain Non-Vote 38,665,307 7,326,124 38,437 1,750,862

Executive Compensation:
Votes For Votes Against Abstain Non-Vote 31,864,841 14,120,824 44,203 1,750,862


Ratification of Auditors:
Votes For Votes Against Abstain
47,191,797 578,154 10,779

  Add HAE to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for HAE - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.